Pfizer shares climb 1.15 percent

By Sumit Modi

Shares of New York-based pharmaceutical company Pfizer have increased 1.15 percent to $37.31 as it prepares to release this year's second quarter earnings later today.

It is expected that the earnings will reach around 62 cents on revenue of $13.01 billion. This time last year, earnings were 56 cents on revenue of $11.85 billion.

Pfizer also announced this week that it has acquired Bamboo Theapeutics for $150 million, expanding its gene therapy biotechnology expertise. 

Pfizer will take over Bamboo's manufacturing facility and any treatments which are currently in development. It had previously collaborated with Spark Therapeutics to create a treatment for hemophilia B.

According to The Street, Mikael Dolsten, Head of Research and Development at Pfizer, said: "We believe that gene therapy holds the promise of bringing true disease modification for patients suffering from devastating diseases."


Follow @BizReviewUSA and @NellWalkerMG

Read the July issue of Business Review USA & Canada here


Featured Articles

Amelia DeLuca, CSO at Delta Air Lines on Female Leadership

Driving decarbonisation at Delta Air Lines, Chief Sustainability Officer Amelia DeLuca discusses the rise of the CSO and value of more women in leadership

Liz Elting – Driving Equality & Building Billion-$ Business

Founder and CEO Liz Elting Turned Her Passion into Purpose and Created a Billion-Dollar Business While Fighting for Workplace Equality – and Winning

JPMorgan Chase: Committed to supporting the next generation

JPMorgan has unveiled a host of new and expanded philanthropic activities totalling US$3.5 million to support the development of apprenticeship programmes

How efficient digital ecosystems became business critical

Technology & AI

Mastercard: Supporting clients at a time of rapid evolution

Digital Strategy

Why Ceridian has boldly rebranded to Dayforce

Human Capital